Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET

Best Pract Res Clin Gastroenterol. 2006;20(5):941-57. doi: 10.1016/j.bpg.2006.04.004.

Abstract

Neoadjuvant or adjuvant multimodality therapy in oesophageal cancer is introduced in an effort to improve prognosis. However, in a substantial fraction of patients there is no response to this non-surgical therapy. Non-invasive imaging modalities such as computed tomography (CT), endoscopic ultrasound (EUS) and 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) have been evaluated for assessing patient response to therapy, and these are described in this review. Currently, FDG-PET seems to be the best available tool for neoadjuvant therapy response assessment in oesophageal cancer.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / therapy
  • Carcinoma, Squamous Cell / diagnosis*
  • Carcinoma, Squamous Cell / therapy
  • Clinical Trials as Topic
  • Endosonography*
  • Esophageal Neoplasms / diagnosis*
  • Esophageal Neoplasms / therapy
  • Fluorodeoxyglucose F18*
  • Humans
  • Neoadjuvant Therapy*
  • Positron-Emission Tomography*
  • Radiopharmaceuticals
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18